Association between sarcoidosis and diabetes mellitus: a systematic review and meta-analysis

We aimed to study the outcomes of COVID‐19 in paediatric cancer patients. On 26 October 2021, we did a systematic search for relevant articles in seven electronic databases followed by manual search. We included cancer patients aged ≤18 years. Event rates and the 95% confidence interval (95%CI) were used to report the results. We included 21 papers after screening of 2759 records. The pooled rates of hospitalisation, intensive care unit (ICU) admission and mortality were 44% (95%CI: 30–59), 14% (95%CI: 9–21) and 9% (95%CI: 6–12), respectively. Moreover, subgroup analysis revealed that high income countries had better COVID‐19 outcomes compared to upper middle income countries and lower middle income countries in terms of hospitalisation 30% (95%CI: 17–46), 60% (95%CI: 29–84) and 47% (95%CI: 36–58), ICU admission 7% (95%CI: 1–32), 13% (95%CI: 7–23) and 18% (95%CI: 6–41), and mortality 3% (95%CI: 2–5), 12% (95%CI: 8–18) and 13% (95%CI: 8–20), in order. In general, absence of specific pharmacologic intervention to prevent infection with the scarcity of vaccination coverage data among paediatric groups and its impact, high priority caution is required to avoid SARS‐CoV‐2 infection among paediatric cancer patients. Furthermore, our results highlight the importance of promoting care facilities for this vulnerable population in low and middle income regions to ensure quality care among cancer patients during pandemic crisis.

show abstract

“…18 The net results of the quality of each paper were reported using the same score reported in earlier published systematic reviews. 19 , 20 …”

Section: Methodsmentioning

confidence: 99%

“…We rated the quality of evidence using the National Institutes of Health quality assessment tool 18 . The net results of the quality of each paper were reported using the same score reported in earlier published systematic reviews 19,20 …”

Section: Methodsmentioning

confidence: 99%

COVID‐19 outcomes in paediatric cancer: A large scale pooled meta‐analysis of 984 cancer patients

El‐Qushayri

Benmelouka²,

Dahy

et al. 2022

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although we tailored the search strategy based on each database, the following search terms were the main components: (“Ischemic attack” OR “transient ischemic attack” OR “TIA * ” OR “brain TIA” OR “posterior circulation transient ischemic attack” OR “anterior circulation transient ischemic attack” OR “transient cerebral ischemia” OR “transient brainstem ischemia”) AND (“stroke” OR “CVA” OR “CVS” OR “cerebrovascular accident * ” OR “cerebrovascular stroke” OR “hemorrhagic stroke” OR “thrombotic stroke” OR “cerebral infarction” OR “acute stroke * ” OR “cerebral stroke * ” OR “brainstem infarction” OR “lacunar infarction” OR “ischemic stroke” OR “lacunar stroke” OR “cardio-embolic stroke” OR “brainstem ischemia”) AND (“Ischemic preconditioning” OR “ischemic preconditioning” OR “ischemic preconditioning” OR “preconditioning”). In addition, we did a manual search of references in the included papers to avoid missing relevant studies ( 25 ). Finally, we included all original studies with no publication date or language restrictions to prevent bias from missing any relevant papers.…”

Section: Methodsmentioning

confidence: 99%

Transient Ischemic Attacks Preceding Ischemic Stroke and the Possible Preconditioning of the Human Brain: A Systematic Review and Meta-Analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Stroke is a leading cause of mortality and disability worldwide. Transient ischemic attack (TIA) is defined as transient brain ischemia with temporary neurological deficits. In animal models, prior TIA seems to enhance brain ischemic tolerance to withstand further ischemic events, which might be explained by brain preconditioning. Thus, this review aims to formulate evidence of whether TIAs can induce positive preconditioning and enhance the functional outcomes in patients suffering from subsequent ischemic strokes. Five databases were searched (PubMed, Embase, SAGE, Web of Science, and Scopus), and twelve studies were included in the quantitative analysis. Studies were eligible when comparing patients with acute ischemic stroke (AIS) and previous TIA with those with AIS without TIA. Comparisons included the National Institute of Health Stroke Scale (NIHSS) score at admission and 7 days from the stroke event, modified Rankin score (mRS), and Trial of ORG 10,172 in Acute Stroke Treatment (TOAST) classification. Odds ratio (OR), mean difference (MD), and 95% confidence interval (CI) were used to describe our results using the random effect model. Our results revealed that patients with stroke and prior TIAs had lower NIHSS scores at admission than those without prior TIAs. However, the NIHSS score was not significantly different between the two groups at 7 days. Furthermore, there was no statistically significant difference between both groups in terms of mortality. Despite the differences in the admission mRS score groups, patients with prior TIAs had lower mRS scores at discharge.

show abstract

“…Several studies have shown that type-2 diabetes (T2D) is more prevalent in patients with sarcoidosis compared with age- and sex-matched controls [ 130–133 ]. However, to what extent the increased risk of T2D is accounted for by glucocorticoid (GC) use is unclear.…”

Section: Metabolic Conditions and Other Comorbiditiesmentioning

confidence: 99%

Comorbidities of sarcoidosis

et al. 2022

View full text Add to dashboard Cite

Sarcoidosis is a heterogeneous disease, which can affect virtually every body organ, even though lungs and intra thoracic lymph nodes are almost universally affected. The presence of noncaseating granulomas is the histopathological hallmark of the disease, and clinical picture depends on the organs affected. Data about interaction between sarcoidosis and comorbidities, such as cardiovascular and pulmonary diseases, autoimmune disorders, malignancy and drug-related adverse events are limited. Several lung conditions can be associated with sarcoidosis, such as pulmonary hypertension and fibrosis, making it difficult sometimes the differentiation between complications and distinctive pathologies. Their coexistence may complicate the diagnosis of sarcoidosis and contribute to the highly variable and unpredictable natural history, particularly if several diseases are recognised. A thorough assessment of specific disorders that can be associated with sarcoidosis should always be carried out, and future studies will need to evaluate sarcoidosis not only as a single disorder, but also in the light of possible concomitant conditions. Key messages Comorbidities in sarcoidosis are common, especially cardiovascular and pulmonary diseases. In the diagnostic workup, a distinction must be made between sarcoidosis-related complaints and complaints caused by other separate disorders. It can be very difficult to distinguish between complications of sarcoidosis and other concomitant conditions. The coexistence of multiple conditions may complicate the diagnosis of sarcoidosis, affect its natural course and response to treatment.

show abstract

Association between sarcoidosis and diabetes mellitus: a systematic review and meta-analysis

Cited by 15 publications

References 55 publications

COVID‐19 outcomes in paediatric cancer: A large scale pooled meta‐analysis of 984 cancer patients

COVID‐19 outcomes in paediatric cancer: A large scale pooled meta‐analysis of 984 cancer patients

Transient Ischemic Attacks Preceding Ischemic Stroke and the Possible Preconditioning of the Human Brain: A Systematic Review and Meta-Analysis

Comorbidities of sarcoidosis

Contact Info

Product

Resources

About